ZNF431

Summary

ZNF431 (zinc finger protein 431, HGNC:20809) is a protein-coding gene on chromosome 19p12, encoding Zinc finger protein 431 (Q8TF32). Sequence-specific DNA binding transcriptional repressor.

This gene encodes a member of the Krueppel C2H2-type zinc-finger family of proteins. The encoded protein may negatively regulate transcription of target genes, including the hedgehog signaling pathway receptor patched 1, by interacting with histone deacetylases. Mutations in this gene may be associated with non-syndromic facial clefting in human patients.

Source: NCBI Gene 170959 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 80 total
• MANE Select transcript: NM_133473

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20809
Approved symbol	ZNF431
Name	zinc finger protein 431
Location	19p12
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1969
Ensembl gene	ENSG00000196705
Ensembl biotype	protein_coding
OMIM	619505
Entrez	170959

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 9 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000311048, ENST00000593426, ENST00000594425, ENST00000594821, ENST00000598331, ENST00000599296, ENST00000600692, ENST00000909422, ENST00000937689, ENST00000949854, ENST00000949855

RefSeq mRNA: 4 — MANE Select: NM_133473 NM_001319124, NM_001319126, NM_001319127, NM_133473

CCDS: CCDS32979

Canonical transcript exons

ENST00000311048 — 5 exons

Exon	Start	End
ENSE00001333108	21182623	21196053
ENSE00001703971	21143551	21143643
ENSE00001730504	21166335	21166461
ENSE00001769618	21167571	21167666
ENSE00003141770	21142040	21142186

Expression profiles

Bgee: expression breadth ubiquitous, 244 present calls, max score 96.13.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 21.0383 / max 426.1748, expressed in 1732 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
174883	19.7512	1730
174884	1.2871	681

Top tissues by expression

251 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	96.13	gold quality
buccal mucosa cell	CL:0002336	93.84	gold quality
adrenal tissue	UBERON:0018303	90.26	gold quality
oral cavity	UBERON:0000167	89.20	gold quality
esophagus mucosa	UBERON:0002469	88.58	gold quality
corpus epididymis	UBERON:0004359	87.79	gold quality
left ovary	UBERON:0002119	86.41	gold quality
ovary	UBERON:0000992	86.34	gold quality
calcaneal tendon	UBERON:0003701	86.02	gold quality
amniotic fluid	UBERON:0000173	85.34	gold quality
right adrenal gland cortex	UBERON:0035827	85.08	gold quality
right adrenal gland	UBERON:0001233	84.57	gold quality
vagina	UBERON:0000996	84.56	gold quality
right ovary	UBERON:0002118	84.46	gold quality
tibia	UBERON:0000979	84.43	gold quality
ganglionic eminence	UBERON:0004023	84.38	gold quality
embryo	UBERON:0000922	84.37	gold quality
oviduct epithelium	UBERON:0004804	84.31	gold quality
esophagus squamous epithelium	UBERON:0006920	84.19	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.02	gold quality
thymus	UBERON:0002370	83.94	gold quality
left adrenal gland	UBERON:0001234	83.66	gold quality
adrenal gland	UBERON:0002369	83.65	gold quality
colonic epithelium	UBERON:0000397	83.46	gold quality
skin of abdomen	UBERON:0001416	83.37	gold quality
secondary oocyte	CL:0000655	83.32	gold quality
left adrenal gland cortex	UBERON:0035825	83.30	gold quality
bone marrow cell	CL:0002092	83.17	gold quality
lower lobe of lung	UBERON:0008949	82.97	gold quality
adrenal cortex	UBERON:0001235	82.96	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.25
E-GEOD-86618	no	97.54
E-MTAB-10137	no	88.90

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
PTCH1

miRNA regulators (miRDB)

90 targeting ZNF431, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-10523-5P	99.91	69.22	2038
HSA-MIR-1297	99.91	73.41	3162
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-LET-7G-3P	99.85	70.43	1929
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-1299	99.77	71.24	2389

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
danio_rerio		ENSDARG00000099025

Paralogs (18): ZNF430 (ENSG00000118620), ZNF92 (ENSG00000146757), ZNF66 (ENSG00000160229), ZNF22 (ENSG00000165512), ZNF680 (ENSG00000173041), ZNF114 (ENSG00000178150), ZFP41 (ENSG00000181638), ZNF730 (ENSG00000183850), ZNF479 (ENSG00000185177), ZNF626 (ENSG00000188171), ZNF100 (ENSG00000197020), ZNF257 (ENSG00000197134), ZNF98 (ENSG00000197360), ZNF675 (ENSG00000197372), ZNF273 (ENSG00000198039), ZNF737 (ENSG00000237440), ZNF253 (ENSG00000256771), ZNF723 (ENSG00000268696)

Protein

Protein identifiers

Zinc finger protein 431 — Q8TF32 (reviewed: Q8TF32)

All UniProt accessions (5): Q8TF32, M0QXY3, M0QZG4, M0QZN7, M0R1H8

UniProt curated annotations — full annotation on UniProt →

Function. Sequence-specific DNA binding transcriptional repressor. Represses target gene transcription by recruiting HDAC1 and HDAC2 histone deacetylases. Acts as a specific transcriptional repressor for PTCH1 during embryonic development. Required for osteoblast differentiation and sonic hedgehog/SHH signaling response. Binds to the consensus site 5’-GCGCCC-3’ in the promoter of PTCH1.

Subunit / interactions. Interacts (via KRAB domain) with HDAC2; the interaction is direct. Interacts (via KRAB domain) with HDAC1.

Subcellular location. Nucleus.

Domain organisation. The KRAB domain is necessary for its repressive activity.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

RefSeq proteins (4): NP_001306053, NP_001306055, NP_001306056, NP_597730* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR050329	GLI_C2H2-zinc-finger	Family

Pfam: PF00096, PF01352, PF13465

UniProt features (17 total): zinc finger region 13, chain 1, domain 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TF32-F1	70.41	0.13

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway

MSigDB gene sets: 64 (showing top): GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION, chr19p12, DODD_NASOPHARYNGEAL_CARCINOMA_UP, AACTTT_UNKNOWN, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, OSMAN_BLADDER_CANCER_DN, TGGAAA_NFAT_Q4_01, GOMF_CHROMATIN_BINDING, GOBP_REGULATION_OF_DNA_BINDING_TRANSCRIPTION_FACTOR_ACTIVITY, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_DN, SENGUPTA_NASOPHARYNGEAL_CARCINOMA_UP, GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II, GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II

GO Biological Process (5): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of DNA-templated transcription (GO:0006355), cell differentiation (GO:0030154), obsolete negative regulation of DNA-binding transcription factor activity (GO:0043433), positive regulation of transcription by RNA polymerase II (GO:0045944)

GO Molecular Function (7): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), chromatin binding (GO:0003682), zinc ion binding (GO:0008270), transcription cis-regulatory region binding (GO:0000976), DNA binding (GO:0003677), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of transcription by RNA polymerase II	3
transcription by RNA polymerase II	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
negative regulation of DNA-templated transcription	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
cellular developmental process	1
positive regulation of DNA-templated transcription	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
binding	1
transition metal ion binding	1
transcription regulatory region nucleic acid binding	1
sequence-specific double-stranded DNA binding	1
nucleic acid binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

560 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF431	PGM3	O95394	436
ZNF431	GLB1L2	Q8IW92	417
ZNF431	NBPF20	P0DPF2	412
ZNF431	DOCK8	Q8NF50	397
ZNF431	KRT37	O76014	370
ZNF431	KRT38	O76015	368
ZNF431	GOLGA6L4	A6NEF3	358
ZNF431	NUDT4B	A0A024RBG1	350
ZNF431	APOL4	Q9BPW4	348
ZNF431	TMF1	P82094	273
ZNF431	CARD11	Q9BXL7	273
ZNF431	POLR3G	O15318	271
ZNF431	GOLGA6L6	A8MZA4	269
ZNF431	RASSF8	Q8NHQ8	269
ZNF431	NPIPB6	E9PJ23	249

IntAct

24 interactions, top by confidence:

A	B	Type	Score
POLR2F	POLR3A	psi-mi:“MI:0914”(association)	0.640
ZNF512	ZNF724	psi-mi:“MI:0914”(association)	0.530
ZNF431	TYRP1	psi-mi:“MI:0914”(association)	0.530
ZNF431	ANXA7	psi-mi:“MI:0915”(physical association)	0.370
CDKN1A	ZNF431	psi-mi:“MI:0915”(physical association)	0.370
ZNF431	SMN1	psi-mi:“MI:0915”(physical association)	0.370
TK1	ZNF431	psi-mi:“MI:0915”(physical association)	0.370
APP	ZNF724	psi-mi:“MI:0914”(association)	0.350
CDX1	ZNF724	psi-mi:“MI:0914”(association)	0.350
RPL27A	ZNF320	psi-mi:“MI:0914”(association)	0.350
NOP2	ZNF320	psi-mi:“MI:0914”(association)	0.350
NOTCH2	ZNF320	psi-mi:“MI:0914”(association)	0.350
LTBP2	ZNF320	psi-mi:“MI:0914”(association)	0.350
SPANXN2	ZNF320	psi-mi:“MI:0914”(association)	0.350
RPL13A	GTPBP10	psi-mi:“MI:0914”(association)	0.350
ANOS1	ZNF724	psi-mi:“MI:0914”(association)	0.350
TRIM63	ZNF431	psi-mi:“MI:0915”(physical association)	0.000
TRIM55	ZNF431	psi-mi:“MI:0915”(physical association)	0.000
menB	ZNF431	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (27): TYRP1 (Affinity Capture-MS), ZNF431 (Affinity Capture-MS), ICAM3 (Affinity Capture-MS), ZNF431 (Affinity Capture-MS), ZNF431 (Affinity Capture-MS), ZNF431 (Affinity Capture-RNA), ZNF431 (Affinity Capture-MS), ZNF431 (Two-hybrid), ZNF431 (Two-hybrid), ZNF431 (Affinity Capture-MS), ZNF431 (Affinity Capture-MS), ZNF431 (Affinity Capture-MS), ZNF431 (Affinity Capture-MS), ZNF431 (Affinity Capture-MS), ZNF431 (Affinity Capture-MS)

ESM2 similar proteins: A6NDX5, A6NK75, A6NNF4, A6NP11, B4DXR9, B7Z6K7, C9JN71, O43361, O75290, O75373, P0CJ79, P0DKX0, P17019, P17021, P17035, P17039, P35789, Q02386, Q03938, Q08AN1, Q13106, Q15928, Q3ZCX4, Q5R9F0, Q5SXM1, Q68EA5, Q6P9A1, Q6PDB4, Q6ZN06, Q6ZN08, Q6ZNG1, Q76KX8, Q86V71, Q86XN6, Q8IYB9, Q8N4W9, Q8NEP9, Q8TBZ8, Q8TC21, Q8TF32

Diamond homologs: A0A1W2PQL4, A6NK75, A6NN14, A6NNF4, A6NP11, A8MQ14, A8MTY0, A8MUV8, A8MXY4, B4DX44, B4DXR9, E9PYI1, O14628, O43345, O75290, O75346, O75373, O75437, O95780, P0CB33, P0DKX0, P0DPD5, P16373, P17019, P17038, P21506, P35789, P52736, P52738, P52744, Q03923, Q03924, Q03936, Q03938, Q05481, Q14586, Q14593, Q14929, Q15928, Q3KNS6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

80 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	72
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1212 predictions. Top by Δscore:

Variant	Effect	Δscore
19:21166329:TTTCA:T	acceptor_loss	1.0000
19:21166331:TCA:T	acceptor_loss	1.0000
19:21166333:A:G	acceptor_loss	1.0000
19:21166333:AG:A	acceptor_gain	1.0000
19:21166334:G:GA	acceptor_loss	1.0000
19:21166334:G:GT	acceptor_gain	1.0000
19:21166334:GG:G	acceptor_gain	1.0000
19:21166334:GGA:G	acceptor_gain	1.0000
19:21166334:GGAGA:G	acceptor_gain	1.0000
19:21166460:GG:G	donor_gain	1.0000
19:21166461:GG:G	donor_gain	1.0000
19:21166462:G:GG	donor_gain	1.0000
19:21167564:A:AG	acceptor_gain	1.0000
19:21167663:CCAG:C	donor_loss	1.0000
19:21167664:CAGG:C	donor_loss	1.0000
19:21167665:AG:A	donor_loss	1.0000
19:21167666:GG:G	donor_loss	1.0000
19:21167667:G:A	donor_loss	1.0000
19:21142152:C:G	donor_gain	0.9900
19:21142184:ATGGT:A	donor_loss	0.9900
19:21142185:TGGT:T	donor_loss	0.9900
19:21142187:GT:G	donor_loss	0.9900
19:21142188:T:G	donor_loss	0.9900
19:21143022:GTCT:G	donor_gain	0.9900
19:21143023:TCTT:T	donor_gain	0.9900
19:21143545:CCATA:C	acceptor_loss	0.9900
19:21143546:CATAG:C	acceptor_loss	0.9900
19:21143548:TA:T	acceptor_loss	0.9900
19:21143549:A:AC	acceptor_loss	0.9900
19:21143549:A:AG	acceptor_gain	0.9900

AlphaMissense

3848 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:21183696:T:C	F465L	0.992
19:21183698:T:A	F465L	0.992
19:21183698:T:G	F465L	0.992
19:21183780:T:C	F493L	0.990
19:21183782:T:A	F493L	0.990
19:21183782:T:G	F493L	0.990
19:21183787:G:C	R495P	0.987
19:21183360:T:C	F353L	0.985
19:21183362:T:A	F353L	0.985
19:21183362:T:G	F353L	0.985
19:21183444:T:C	F381L	0.984
19:21183446:T:A	F381L	0.984
19:21183446:T:G	F381L	0.984
19:21183612:T:C	F437L	0.984
19:21183614:T:A	F437L	0.984
19:21183614:T:G	F437L	0.984
19:21183528:T:C	F409L	0.983
19:21183530:T:A	F409L	0.983
19:21183530:T:G	F409L	0.983
19:21183108:T:C	F269L	0.981
19:21183110:T:A	F269L	0.981
19:21183110:T:G	F269L	0.981
19:21183192:T:C	F297L	0.976
19:21183194:C:A	F297L	0.976
19:21183194:C:G	F297L	0.976
19:21183864:T:C	F521L	0.974
19:21183866:T:A	F521L	0.974
19:21183866:T:G	F521L	0.974
19:21183276:T:C	F325L	0.973
19:21183278:T:A	F325L	0.973

dbSNP variants (sampled 300 via entrez): RS1000091678 (19:21174555 T>C), RS1000271698 (19:21192242 C>T), RS1000312121 (19:21180714 C>T), RS1000388394 (19:21192472 T>A), RS1000390643 (19:21142463 C>T), RS1000405203 (19:21150906 C>A), RS1000511353 (19:21172634 C>T), RS1000543765 (19:21169436 A>T), RS1000584996 (19:21173049 A>G), RS1000608714 (19:21163293 G>A), RS1000648583 (19:21169647 A>G), RS1000855702 (19:21187100 A>G), RS1000865576 (19:21177128 T>C), RS1000906832 (19:21160166 A>G), RS1000917254 (19:21182052 A>C)

Disease associations

OMIM: gene MIM:619505 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	2
Cadmium Chloride	increases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
TAK-243	increases sumoylation	1
triphenyl phosphate	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
jinfukang	affects cotreatment, decreases expression	1
theaflavin-3,3’-digallate	affects expression	1
Resveratrol	affects cotreatment, increases expression	1
Temozolomide	increases expression	1
Leflunomide	increases expression	1
Acetaminophen	increases expression	1
Air Pollutants	increases abundance, affects expression	1
Benzo(a)pyrene	decreases methylation	1
Cisplatin	affects cotreatment, decreases expression	1
Doxorubicin	decreases expression	1
Gallic Acid	decreases expression	1
Ozone	increases abundance, affects expression	1
Plant Extracts	affects cotreatment, increases expression	1
Silicon Dioxide	decreases expression	1
Testosterone	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Urethane	increases expression	1
Vanadates	decreases expression	1
Okadaic Acid	increases expression	1
Acrylamide	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer